NCT03795441 is a Phase 1 clinical trial of Ad26.RSV.preF in Healthy, sponsored by Janssen Vaccines & Prevention B.V..

Who is sponsoring NCT03795441?

NCT03795441 is sponsored by Janssen Vaccines & Prevention B.V..

What drugs are being tested in NCT03795441?

Interventions in NCT03795441: Ad26.RSV.preF.

Is NCT03795441 still recruiting?

NCT03795441 is currently completed. Last updated 30 August 2019.

Last reviewed 2019-08-30 · How we verify

NCT03795441

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Shedding Study of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF) Vaccine in Adults

Completed Phase 1 Last updated 30 August 2019

What this trial tests

Phase 1 trial testing Ad26.RSV.preF in Healthy in 24 participants. Completed in 28 July 2019.

Timeline

7 January 2019

Primary endpoint
28 July 2019

28 July 2019

Quick facts

Lead sponsor	Janssen Vaccines & Prevention B.V.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	24
Start date	7 January 2019
Primary completion	28 July 2019
Estimated completion	28 July 2019
Sites	1 location across Belgium

Drugs / interventions tested

Ad26.RSV.preF — full drug profile →

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Janssen Vaccines & Prevention B.V. — full company profile →

Who can join

18 and older, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the shedding and kinetics of the Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF) vaccine after one intramuscular injection of Ad26.RSV.preF in adults.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape.
Mazur NI, Terstappen J, Baral R, Bardají A, et al · · 2023 · cited 294× · PMID 35952703 · DOI 10.1016/s1473-3099(22)00291-2
Virus vaccines: proteins prefer prolines.
Sanders RW, Moore JP. · · 2021 · cited 84× · PMID 33705704 · DOI 10.1016/j.chom.2021.02.002
Current State and Challenges in Developing Respiratory Syncytial Virus Vaccines.
Biagi C, Dondi A, Scarpini S, Rocca A, et al · · 2020 · cited 45× · PMID 33187337 · DOI 10.3390/vaccines8040672
Respiratory Syncytial Virus (RSV): A Comprehensive Overview From Basic Biology to Clinical Prevention and Control.
Shi J, Huang X, Ye C, Lu Y, et al · · 2026 · PMID 41261734 · DOI 10.1002/med.70025

Verify or expand the search:

Other trials of Ad26.RSV.preF

Trials testing the same drug.

NCT03606512 — A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial · Phase 1, PHASE2 · completed
NCT03339713 — A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vac · Phase 2 · completed
NCT03334695 — An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory · Phase 2 · completed

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Janssen Vaccines & Prevention B.V. trials

Trials by the same sponsor.

NCT05901636 — A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults · Phase 1, PHASE2 · completed
NCT05327816 — A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Year · Phase 1, PHASE2 · terminated
NCT05091307 — A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults · Phase 3 · completed
NCT05101486 — A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years · Phase 3 · completed
NCT05083585 — A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Ag · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03795441 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Janssen Vaccines & Prevention B.V.
Last refreshed: 30 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03795441.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing